Jump to content

3,4-Methylenedioxy-N-hydroxyamphetamine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
mNo edit summary
m task, replaced: : → :
 
(32 intermediate revisions by 22 users not shown)
Line 1: Line 1:
{{Short description|Psychedelic amphetamine}}
{{Drugbox
{{DISPLAYTITLE:3,4-Methylenedioxy-''N''-hydroxyamphetamine}}
⚫
| IUPAC_name = (±)-1-(benzo[d][1,3]dioxol-5-yl)-''N''-hydroxylpropan-2-amine
{{Infobox drug
| image = 3,4-MDOH.png
| drug_name = 3,4-Methylenedioxy-''N''-hydroxyamphetamine
⚫
| IUPAC_name = 1-(1,3-Benzodioxol-5-yl)-''N''-hydroxypropan-2-amine
| image = MDOH_structure.svg
| width = 200px
| width = 200px


Line 7: Line 10:
| tradename =
| tradename =
| pregnancy_category =
| pregnancy_category =
| legal_status =
| legal_CA = Schedule I
| legal_UK = Class A
⚫
| routes_of_administration =
| legal_DE = Anlage I
| legal_US = Schedule I
| legal_UN = P I
⚫
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
Line 15: Line 22:
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number = 74698-47-8
| CAS_number = 74698-47-8
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SJE1T2B1A7
| ATC_prefix = none
| ATC_prefix = none
| ATC_suffix =
| ATC_suffix =
| PubChem = 98528
| PubChem = 98528
| DrugBank =
| DrugBank =
| KEGG = C22807
| ChemSpiderID = 88979
| ChemSpiderID = 88979


<!--Chemical data-->
<!--Chemical data-->
| C=10 | H=13 | N=1 | O=3
| C=10 | H=13 | N=1 | O=3
| molecular_weight = 195.22 g/mol
| smiles = CC(CC1=CC2=C(C=C1)OCO2)NO
| smiles = CC(CC1=CC2=C(C=C1)OCO2)NO
}}
}}


'''3,4-Methylenedioxy-''N''-hydroxyamphetamine''' ('''MDOH''', '''MDH''') is an [[entactogen]], [[psychedelic_drug|psychedelic]], and [[stimulant]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] [[chemical class]]es. It is the ''N''-[[hydroxy]] [[homology (chemistry)|homologue]] of [[methylenedioxyamphetamine|MDA]], and the ''N''-[[desmethyl]] homologue of [[methylenedioxyhydroxymethamphetamine|MDHMA]]. MDOH was first [[Organic synthesis|synthesized]] and [[assay]]ed by [[Alexander Shulgin]].<ref>{{CitePiHKAL}}</ref> In his book ''[[PiHKAL]]'' (''Phenethylamines i Have Known And Loved''), Shulgin listed the dosage range as 100-160 mg, and the duration as approximately 3-6 hours.<ref>{{CitePiHKAL}}</ref> He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature.<ref>{{CitePiHKAL}}</ref> He also mentioned several negative side effects also seen with [[MDMA]] ("Ecstasy") such as difficulty urinating and internal dryness.<ref>{{CitePiHKAL}}</ref>
'''3,4-Methylenedioxy-''N''-hydroxyamphetamine''' ('''MDOH''', '''MDH''', '''N-hydroxytenamphetamine''') is an [[entactogen]], [[psychedelic drug|psychedelic]], and [[stimulant]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] [[chemical class]]es.<ref name="de_Boer_2004">{{cite journal | vauthors = de Boer D, Bosman I | title = A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs | journal = Pharmacy World & Science | volume = 26 | issue = 2 | pages = 110–113 | date = April 2004 | pmid = 15085947 | doi = 10.1023/b:phar.0000018600.03664.36 }}</ref> It is the ''N''-[[hydroxyl|hydroxy]] [[Homologous series|homologue]] of [[3,4-Methylenedioxyamphetamine|MDA]], and the ''N''-[[desmethyl]] homologue of [[methylenedioxyhydroxymethamphetamine|MDHMA]]. MDOH was first [[Organic synthesis|synthesized]] and [[assay]]ed by [[Alexander Shulgin]].<ref name = "CitePiHKAL">{{CitePiHKAL|name-list-style = vanc }}</ref> In his book ''[[PiHKAL]]'' (''Phenethylamines i Have Known And Loved''), Shulgin listed the dosage range as 100–160&nbsp;mg, and the duration as approximately 3–6 hours.<ref name = "CitePiHKAL" /> He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature.<ref name = "CitePiHKAL" /> He also mentioned several negative side effects also seen with [[MDMA]] ("Ecstasy") such as difficulty urinating and internal dryness.<ref name = "CitePiHKAL" />

== See also ==
* [[Substituted methylenedioxyphenethylamines]]


== References ==
== References ==
Line 43: Line 49:
* [http://pihkal.info/read.php?domain=pk&id=114 MDOH entry in PiHKAL • info]
* [http://pihkal.info/read.php?domain=pk&id=114 MDOH entry in PiHKAL • info]


{{Entactogens}}
{{Entactogens|state=expanded}}
{{Hallucinogens}}
{{Hallucinogens}}
{{Stimulants}}
{{Stimulants}}
{{Monoamine releasing agents}}
{{Adrenergics}}
{{Dopaminergics}}
{{Serotonergics}}
{{Phenethylamines}}
{{Phenethylamines}}


{{DEFAULTSORT:Methylenedioxy-N-hydroxyamphetamine, 3, 4-}}
⚫
[[Category:Amphetamines]]
[[Category:Substituted amphetamines]]
⚫
[[Category:Designer drugs]]
[[Category:Benzodioxoles]]
[[Category:Benzodioxoles]]
[[Category:Serotonin-norepinephrine-dopamine releasing agents]]
[[Category:Entactogens and empathogens]]
[[Category:Hydroxylamines]]
[[Category:Human drug metabolites]]



{{hallucinogen-stub}}
{{nervous-system-drug-stub}}

Latest revision as of 03:41, 10 May 2024

3,4-Methylenedioxy-N-hydroxyamphetamine
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • 1-(1,3-Benzodioxol-5-yl)-N-hydroxypropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13NO3
Molar mass195.218 g·mol−1
3D model (JSmol)
  • CC(CC1=CC2=C(C=C1)OCO2)NO

3,4-Methylenedioxy-N-hydroxyamphetamine (MDOH, MDH, N-hydroxytenamphetamine) is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes.[1] It is the N-hydroxy homologue of MDA, and the N-desmethyl homologue of MDHMA. MDOH was first synthesized and assayed by Alexander Shulgin.[2] In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 3–6 hours.[2] He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature.[2] He also mentioned several negative side effects also seen with MDMA ("Ecstasy") such as difficulty urinating and internal dryness.[2]

References

[edit]
  1. ^ de Boer D, Bosman I (April 2004). "A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs". Pharmacy World & Science. 26 (2): 110–113. doi:10.1023/b:phar.0000018600.03664.36. PMID 15085947.
  2. ^ a b c d Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
[edit]


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=3,4-Methylenedioxy-N-hydroxyamphetamine&oldid=1223135563"